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and also has in vitro blocking activity to ATP-binding cassette (ABC) 
transporters. We evaluated the activity and toxicity of GP in NSCLC 
pts who failed prior G or both G and T (G/T). 
Methods: Eligibilities were NSCLC failed G, measurable lesion, 
ECOG PS0-3 and life expectancy > 6 wks. They were chemonaive 
or had failed prior chemotherapeutic regimen(s)(CTR). Treatment 
consisted of oral G (250 mg) daily and intravenous P (60 mg/m2) d1, 
8, 15 q4w. Primary endpoint was response rate (RR) and secondary 
endpoints were disease control rate (DCR), time to progression (TTP), 
overall survival (OS) and toxicity. GP was also tested in vitro in an 
adenoca. cell line with wild type EGFR and its p-glycoprotein (pgp) 
expressing subclones. 
Results: From Sep 2004 to Mar 2007, 53 pts were enrolled and eligible 
for activity and toxicities: M/F 21/32; median age 64; PS 1/2/3 25/25/3; 
stage IIIB/IV 5/48; adeno/squ/others 44/4/5. Of the 53 pts who failed 
G, 10 were chemonaive, 8 had prior G and non T agents, 35 had prior 
G/T (docetaxel 28, paclitaxel 11). Median prior CTR was 3 (0-6). A 
total of 436 cycles (median 6, range 1-18) were given. RRs were 22.6% 
and 22.9%, DCRs (PR+SD) 45.3% and 45.7%, TTP 135d and 99d, OS 
265d and 233d for overall and G/T groups, respectively. There was a 
trend that prior T resistant pts may have better response than T refrac-
tory ones. G3/4 toxicities were leukopenia 4% and 3%, anemia 2% and 
3%, G3 ﬂu-like symptoms 16% and 14% in overall and G/T group, 
respectively. In vitro drug testing showed that G could reverse Pgp as-
sociated P resistance in a dose dependent fashion. 
Conclusions: GT showed a moderate activity for salvage treatment 
in pts who failed prior G or G/T. G may aid P or partially reverse its 
resistance. 
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Electrocautery in combined modality with chemotherapy and 
radiotherapy in treatment of non-small cell lung cancer affecting 
central airways
Tudik, Ivan 
Specialized Hospital of Respiratory Diseases, Poprad, Slovakia
Background and Methods: Electrocautery (EC) is a method that uses 
alternating current for thermal destruction of tissue. Depending on the 
voltage and current, electrocautery causes coagulation or vaporiza-
tion and carbonization of tissue. During the period 08/2002 - 02/2007 
electrocautery in local anesthesy was used in treatment of 37 pts. with 
various indications. The author presents results of treatment in 14 
patients with inoperable locally advanced non-small cell lung cancer 
predominantly expanding to central airways with only insubstantial 
affecting lung parenchyma and with no metastases (S IIIB). In these 
patients, electrocautery (EC) was combined with chemotherapy (CHT) 
and radiotherapy ( RAT ) or brachyradiotherapy. The ﬁrst dose of 
CHT was given just within the 1st day after EC, preferably platinum 
regimens (CDDP- Vinorelbine 5x, CDDP- Vinblastine 2x, CarboPt 
- Gemcitabine 2x, Vinorelbine monotherapy 2x, Docetaxel 2x, Gemzar 
monotherapy 1x). EC and CHT was used in the ﬁrst-line treatment in 8 
pts. and in the second-line in 6 pts. with relapsed NSCLC. EC was used 
on average twice in one patient ( min. 1, max. 3 ) during the treatment 
time. 
Results: Recanalization of central airways was achieved in all patients 
(100%), complete recanalization was achieved in 6 pts. out of 8 (75%) 
where EC and CHT was used in the ﬁrst-line setting. Treatment can 
be effective even in case of massive endotracheal or endobronchial 
lesions. The overall median survival time was 13 months ( 95% CI 0,0 
- 26,9), median survival time in subgroup of 8 pts., where EC was used 
in the ﬁrst-line setting, was not reached. EC and CHT can be easily and 
safety combined, there were found no 30 days mortality and minimal 
morbidity.
Discussion: There is only limited amount of information regarding 
positive effect of combined EC (or other method of interventional bron-
chology) and CHT/RAT (1,2). A synergic effect of both the methods 
is possible. One explanation for this effect could be the action of heat 
shock proteins, that are regarded as possibly the most potent stimulans 
of immune response in oncology and are used for development of anti-
cancer vaccines (3,4). The other explanation is the thermal pre-impair-
ment of deeper structures of a tumor which facilitates the better action 
of cytostatics. 
Conclusions: Fiberbronchoscopic electrocautery under local anesthesia 
is an effective and safe method in treatment of patients with inoper-
able central NSCLC, which can be used in combined modality with 
chemotherapy and radiotherapy. A synergic effect of electrocautery and 
chemotherapy is possible.
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Radiation pneumonitis (RP) in lung cancer patients treated with 
chemotherapy (CT) and thoracic radiation (TR): Retrospective 
analyses of patients treated at a comprehensive cancer center
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Background: Combined CT and TR is the current standard for locally 
advanced non-small cell lung cancer (NSCLC) and SCLC. Severe 
RP, an important adverse effect of TR, is reported in clinical trials to 
occur in 10% of patients receiving CT and TR. The rate in routine care 
may be higher as patients are not selected based on lung function. We 
conducted a retrospective study to assess the incidence of RP in lung 
cancer patients treated with CT and TR.
Methods: Retrospectively we identiﬁed patients who underwent com-
bined modality therapy (concurrent or sequential CT and TR) for lung 
cancer (NSCLC & SCLC) at our cancer center between January 2001 
and December 2004. Demographic features, RP incidence and grade 
(RTOG criteria), hospitalization rate, and overall survival (OS) were 
assessed.
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Results: 85 patients who met the selection criteria were analyzed. The 
demographic features were - males 61%; Caucasians - 54%; African 
Americans - 38%; history of pulmonary disorder- 41%; NSCLC- 78%; 
PS- 0,1- 92%; Stage III- 89%. The median dose of TR was 5940 cGy. 
Radiation ﬁelds have been retrospectively assessed in 41 patients to 
date. 9 of the 41 patients (22%) received involved ﬁeld radiation. 53 
patients (63%) received Cisplatin/Etoposide and 20 patients (24%) 
received Carboplatin/Paclitaxel. 75 patients (88%) received concurrent 
therapy. 31 patients (36%) developed RP; 15 (18%) had RTOG grade ≥ 
3 RP. Median time to development of RP was 4.6 months. Rate of RP 
in females and males was 42% vs. 33% (p=0.49). Rate of RP in patients 
with history of pulmonary disorder at baseline was 49% as compared to 
28% in others (p=0.068). 1 year hospitalization rate was 74% and 37% 
in RP and non-RP patients (p=0.0015). For all 85 patients, the median 
overall survival (OS) was 19.5 months (95% CI 16.4 - 23.3). Length of 
OS did not differ signiﬁcantly (p = 0.59) between the 31 patients who 
had RP vs. the 54 patients who had no RP (median OS: 19.3 vs. 18.8 
months, respectively). The median survival of the 15 patients who had 
severe RP was 16.6 months.
Conclusions: The rate of severe RP in these 85 lung cancer patients, 
treated off-protocol with CT and TR, is higher than that reported in 
clinical trials. Despite higher morbidity (i.e., increased hospitalization) 
in patients with RP, survival duration did not differ signiﬁcantly by RP 
status.
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Adjuvant docetaxel plus carboplatin versus observation in 
patients with completely resected stage IB-IIIA non-small-cell lung 
cancer: preliminary results of the Chinese Society of Lung Cancer 
randomised controlled trial (CSLC201)
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Background: Four larger clinical trials, IALT, NCIC-JBR10, ANITA 
and Japanese UFT trial, have shown signiﬁcant OS advantages with ad-
juvant chemotherapy. Unless vinorelbine plus cisplatin, whether other 
third generation doublet chemotherapy regimen improves survival of 
patients with non-small-cell lung cancer (NSCLC) is not known. We 
aimed to compare the effect of adjuvant docetaxel plus carboplatin 
versus observation on survival in patients with completely resected 
NSCLC.
Methods: 82 patients with stage IB-IIIA NSCLC from 3 centres in 
China were randomly assigned to 75mg/m(2) docetaxel plus AUC=5 
carboplatin (n=43) or to observation (n=39). The primary endpoint was 
disease free survival (DFS). The second endpoint was overall survival, 
response rate in the chemo group and safety. Analysis was by intention 
to treat. This trial was closed early by the EC as adjuvant chemotherapy 
became a standard therapy for resected NSCLC in 2005.
Results: 43 patients in the chemotherapy group and 39 in the observa-
tion group received their assigned treatment. 45 (54.9%) patients had 
stage IB disease, 20 (24.4%) had stage II disease, and 17 (20.7%) had 
stage IIIA disease. Adenocarcinoma accounted for 62.2% (51 cases, 
Tab.1). The median chemotherapy cycles were 3. After a median 
follow-up of 29.5 months (range 3-51), median disease free survival 
time is not reached in the chemotherapy group and 34 months in the 
observation group (p=0.0173). Median overall survival in both groups 
is not reached (Fig.1). 
Conclusion: Adjuvant docetaxel plus carboplatin extends disease free 
survival in patients with completely resected NSCLC.
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Can the patients with locally advanced non-small cell lung 
cancer (LANSCLC) tolerate 60mg/m2 docetaxel on day 1 and 
30mg/m2 Cisplatin on day 1 and 2 for 2 cycles during concurrent 
radiotherapy (CCRT) after 2-3 cycles of induction chemotherapy?
Yu, Rong Zhu, Guangying Shi, Anhui 
Department of Radiation Oncology, Cancer Hospital, Peking University 
School of Oncology, Beijing, China
Background: CCRT plus consolidation chemotherapy is a standard 
treatment of LANSCLC. But there is still a great controversy about 
the chemotherapy regimen for CCRT. A group of physician in Korean 
found 20mg/m2 docetaxel plus 20mg/m2 cisplatin, weekly is maximum 
tolerated dose for patients with LANSCLC during 6 weeks of 63Gy 
radiotherapy. The purpose of our trial was to determine whether the 
NSCLC patients after 2-3 cycles of induction chemotherapy can toler-
ate the chemotherapy regimen of 60 mg/m2 T and 60mg/m2, 2 cycles in 
6 weeks radiotherapy, based on toxicity. 
Methods: Previously untreated 9 patients with histological/cytologi-
cally proven Stage III non-small-cell lung cancer were eligible after 
induction chemotherapy for 2-3 cycles. Followed a month later by con-
tinual radiotherapy (62-70Gy in 31-35 fractions, 6-7weeks) delivered 
concurrently with cisplatin and docetaxel. The dosage of level 1 was 
of 56 mg/m2 docetaxel, on day 1 and 28mg/m2 cisplatin, on day 1 and 
day 2, 2 cycles during CCRT. The radiotherapy model was conformal 
radiotherapy or intensity modulated radiotherapy. The dosage of level 
2 was 60 mg/m2 docetaxel, on day 1 and 30 mg/m2 on day 1 and day 2. 
Response rate was evaluated as complete remission (CR), partial remis-
sion (PR), stable disease (SD) and progressive disease (PD). 
Results: Nine patients were enrolled, with median age of 58, (43-70). 
Seven patients were male, 2 female. The ECOG scores of 4 patients 
were 0, and ECOG scores of 5 patients were 1. The loss of weight of 
8 patients was 0%, that of one patient was ≤5% in three months before 
diagnosis. Seven patients were with squamous cell carcinoma, 2 with 
adenocarcinoma. The objective response was as follows: PR 8/9, SD 
1/9. The toxicities were showed in table 1.
Conclusions: The patients with LANSCLC can tolerate 60mg/m2 
docetaxel and 60mg/m2 cisplatin for 2 cycles during concurrent radio-
therapy after 2-3 cycles of induction chemotherapy.
